Navigation Links
Mathew to Lead PPD Drug Development Operations and Expansion in India
Date:12/12/2007

Company announces second office in Mumbai

WILMINGTON, N.C., Dec. 12 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced the appointment of Philip Mathew, M.D., as director of strategic development, to lead the company's Phase II-IV operations and expansion in India.

Dr. Mathew will provide strategic leadership for PPD's drug development business on the Indian subcontinent, including clinical project management and patient recruitment for key therapeutic areas. He will also be responsible for identifying and helping to develop new clinical sites and business opportunities as well as liaising with local and national government departments.

"A native of India, Dr. Mathew brings extensive clinical trials experience and in-depth knowledge of the healthcare industry in this country," said Simon Britton, vice president of clinical operations for PPD in Asia. "His leadership will enable us to strengthen our presence in this important global clinical research market as we continue to meet the growing needs of our clients. We are pleased to welcome him to PPD."

The company also announced it is opening a second Mumbai office, where Dr. Mathew will be based. The office, located at the Dynasty facility in the Mumbai business district, expands the company's global footprint for providing clinical services.

Prior to joining PPD, Dr. Mathew was associate medical director at Covance Inc. He had previously served as principal investigator with MDS Pharma Services; attending physician with the Robert Wood Johnson University Hospital; instructor of medicine with the University of Medicine and Dentistry of New Jersey; staff physician with the Clinical Research Center of the Robert Wood Johnson Medical School and University of Medicine and Dentistry of New Jersey; and consultant physician with the Church of South India Mission Hospital.

Dr. Mathew attended St. Joseph's College at Calicut University in Kerala, India, and received bachelor's degrees in medicine and surgery from Calicut Medical College. He earned his medical degree in general medicine from Christian Medical College at Vellore in Tamil Nadu, India. Certified by the American Board of Internal Medicine and in its subspecialty of infectious diseases, Dr. Mathew has authored numerous publications and presentations.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the above-named employee's performance and value to PPD contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-sponsored research sector; loss of or delay in large contracts; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments, such as impairments; competition within the outsourcing industry; continued success in sales growth; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts

Media:

Sue Ann Pentecost

+919 456 5690

sueann.pentecost@rtp.ppdi.com

Analysts/Investors:

Steve Smith

+910 558 7585

stephen.smith@wilm.ppdi.com


'/>"/>
SOURCE PPD, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
5. Global Experts Explore Entire Spectrum of Aids Vaccine Development
6. Vical Names Andrew de Guttadauro Vice President, Corporate Development
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. SemBioSys updates Apo AI development program
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... MONICA, Calif. , March 22, 2017 /PRNewswire/ ... are proud to announce their extended partnership and ... will be headlined by the 21 st ... BIOMEDevice Boston, taking place May 3-4, 2017. ... Advanced Medical Technology Association (ADVAMED) President and CEO, ...
(Date:3/22/2017)... 2017 The global chronic kidney ... report by Transparency Market Research (TMR). The top four ... AbbVie Inc., accounted for a share of only 41.4% ... this market are focusing aggressively on mergers, acquisitions, and ... likely to lead to market consolidation in the next ...
(Date:3/22/2017)... 22, 2017   VWR (NASDAQ: ... product and service solutions to laboratory and ... acquired EPL Archives, Inc., an international biorepository ... entire regulated product research, development and commercialization ... and ancillary services. EPL Archives is widely ...
(Date:3/22/2017)... ... March 21, 2017 , ... Benchworks CEO ... Executive Officer Forum on March 23-24 in San Diego. The event is a ... diagnostic industries. , Benchworks Vice President Christian Meyer will also participate in the ...
Breaking Biology Technology:
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... 2017 Vigilant Solutions , a vehicle ... agencies, announced today the appointment of retired FBI special ... safety business development. Mr. Sheridan brings more ... a focus on the aviation transportation sector, to his ... Mr. Sheridan served as the Aviation Liaison Agent Coordinator ...
(Date:3/16/2017)... March 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... Used combined in one ... ...
Breaking Biology News(10 mins):